← Russell 3000 cross-section

IONS IONIS PHARMACEUTICALS INC

Trailing twelve months to 2026-06-30 · as filed 2026-07-29, not restated
Healthcare

Scale

Market cap
$10.4bn
Revenue TTM
$874m
Net income TTM
$-565m
Free cash flow
$-561m
Composite score
33.9
Sector rank
#694

Valuation

P / E
EV / EBITDA
EV / sales
9.6
FCF yield
-5.37%
Earnings yield vs 10-yr
-10.14pp

Earnings yield vs 10-yr compares what the business earns per pound invested against the 4.73% a 10-year US Treasury note pays for no equity risk. Negative means you are paying up front for growth not yet delivered.

Quality and growth

Net margin
-64.7%
EBITDA margin
-66.3%
ROE
-128.5%
ROIC
Revenue growth
-7.4%

Insider activity, last 90 days

Net open-market
$-18.62m
Buyers
1
Sellers
10

Open-market purchases and sales only. Grants, option exercises, gifts and shares withheld for tax are excluded: they are how people are paid, not what they think.

What management said

Results of Operations The following is a summary of our financial results (in millions): Revenue Total revenue for the three and six months ended June 30, 2026 was $267.9 million and $514.0 million, respectively, compared to $452.0 million and $583.7 million for the same periods in 2025, respectively, and was comprised of the following (in millions): Commercial revenue for the three months and six months ended June 30, 2026 increased 15% and 27%, respectively, compared to the same periods in 2025. This increase was primarily driven by DAWNZERA product sales. …IONIS PHARMACEUTICALS INC, 10-Q, period ended 2026-06-30, filed 2026-07-29

Read the full passage →